BFH772 (VEGFR2 inhibitor): Technical Use & Workflow Guidance

What This Product Solves

BFH772 is a small molecule VEGFR2 inhibitor (CAS 890128-81-1) with high selectivity for the VEGFR2 kinase, a critical target in angiogenesis research. By specifically inhibiting VEGFR2-mediated signaling, BFH772 enables researchers to dissect VEGF-driven angiogenic pathways and evaluate targeted anti-angiogenic strategies in tumor models. Its high affinity (IC50 = 3 nM) and approximately 500-fold selectivity over related kinases (FLK-1, FLT-1, FLT-4) make it particularly useful when clean pathway modulation is required without confounding off-target effects. This product is best suited for workflows that prioritize selectivity, require compatibility with organic solvents, and aim to interrogate VEGFR2-dependent biology, such as tumor angiogenesis research and selective pathway inhibition assays. Conversely, BFH772 is not appropriate for protocols needing water-soluble compounds or non-selective kinase inhibition.

Protocol Parameters

• Solvent Compatibility: DMSO ≥53.4 mg/mL or ethanol ≥15.33 mg/mL | Compound dissolution | Ensures efficient solubilization for in vitro and in vivo workflows; water is not suitable due to compound insolubility | product dossier
• Recommended Storage: -20°C (solid state) | Stock stability | Maintains compound purity and activity; long-term storage of solutions is discouraged due to potential degradation | product dossier
• Assay Selectivity: IC50 (VEGFR2) = 3 nM (selectivity: ~500-fold over FLK-1, FLT-1, FLT-4) | Kinase selectivity assays | Supports specific inhibition of VEGFR2 with low risk of off-target effects in angiogenesis models | product dossier
• Working Solution Preparation: Prepare fresh solutions in DMSO shortly before use | Cell-based or in vivo assays | Reduces risk of compound breakdown and ensures reproducible bioactivity | workflow recommendation
• Quality Control: Purity >96% (COA provided) | Assay validity confirmation | Minimizes risk of experimental interference from impurities | product dossier

Workflow Setup and QC Checklist

• Compound Handling: Thaw BFH772 (VEGFR2 inhibitor) at room temperature before opening to avoid condensation. Always handle under low humidity and reseal promptly to minimize moisture uptake.
• Solution Preparation: Dissolve the required amount in DMSO or ethanol according to solubility limits. Vortex briefly and, if necessary, gently heat (≤37°C) to ensure complete dissolution. Filter sterilize if used in cell-based assays.
• Aliquoting: Prepare single-use aliquots to avoid repeated freeze-thaw cycles, which can degrade compound integrity.
• Quality Control Verification: Confirm batch purity (>96%) and reference the provided certificate of analysis (COA) prior to use in critical assays.
• Assay Controls: Include both vehicle-only (solvent) and positive/negative controls to validate the specificity and efficacy of BFH772 in your system.
• Storage: Store unused solid at -20°C in a desiccated environment. Minimize time spent at room temperature during weighing and solution preparation.

For additional procedural guidance, see "BFH772 (VEGFR2 inhibitor): Technical Guidance & Protocols", which details best practices for compound handling and experimental design in angiogenesis models. "BFH772 (VEGFR2 Inhibitor): Technical Use and Protocol Parameters" further outlines the importance of selectivity and solvent compatibility in workflow planning.

Common Failure Modes and Fixes

• Poor Dissolution: If BFH772 does not fully dissolve in DMSO or ethanol, verify that concentrations do not exceed solubility limits (53.4 mg/mL in DMSO, 15.33 mg/mL in ethanol). Gently heat (≤37°C) and vortex, or sonicate briefly if necessary. Never attempt dissolution in water.
• Loss of Activity: If reduced efficacy is observed, check that the working solution is freshly prepared and not stored for extended periods. Discard aged solutions and re-prepare immediately before use.
• Batch Variability: Always reference the COA for each lot and confirm purity. If unexpected results occur, cross-check with a new aliquot or batch and review all handling steps for possible contamination or degradation.
• Non-specific Effects: If off-target effects are suspected, confirm that experimental concentrations are within recommended ranges for selective VEGFR2 inhibition, and include appropriate negative controls to differentiate VEGFR2-specific outcomes.

Scope and Limitations

• Scope: BFH772 is optimized for research requiring precise inhibition of the VEGFR2 signaling pathway, particularly in angiogenesis and tumor model systems. It is suitable for kinase selectivity studies, pathway dissection, and as a reference inhibitor in anti-angiogenic agent screening.
• Limitations: The compound is insoluble in water, restricting its use to solvent-based assays. It is not designed for protocols demanding broad-spectrum kinase inhibition or for studies targeting non-VEGFR2 pathways. Long-term storage of solutions is not recommended due to potential instability; always prepare fresh working solutions.
• Regulatory Status: BFH772 is a research-use-only reagent and is not intended for diagnostic or therapeutic applications in humans.

Conclusion

BFH772 stands out as a selective VEGFR2 kinase inhibitor for angiogenesis research, with robust selectivity and well-defined solubility characteristics. By adhering to solvent compatibility and storage guidelines, researchers can reliably employ BFH772 in tumor angiogenesis and VEGFR2 pathway inhibition workflows. For full technical details, refer to the BFH772 (VEGFR2 inhibitor) product page at APExBIO, which provides up-to-date product specifications, COA access, and safety data sheets.